Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009

Scandinavian Journal of Rheumatology

Volumn 40, Issue 1, 2011, Pages 8-15

  Neovius, M ^a   Sundstrom A ^a   Simard, J F ^a   Wettermark, B ^a,b   Cars, T ^b   Feltelius, N ^c   Askling, J ^a   Klareskog, L ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM COUNTY COUNCIL   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; TRASTUZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; ARTICLE; CHRONIC INFLAMMATION; CROHN DISEASE; DISEASE DURATION; DISEASE REGISTRY; DRUG COST; DRUG DOSE ESCALATION; DRUG MARKETING; GEOGRAPHIC DISTRIBUTION; HUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SWEDEN; TREATMENT INDICATION; TREATMENT OUTCOME; CLUSTER ANALYSIS; DRUG ANTAGONISM; DRUG INDUSTRY; ECONOMICS; PRESCRIPTION; STATISTICS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG COSTS; DRUG INDUSTRY; DRUG PRESCRIPTIONS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; SMALL-AREA ANALYSIS; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952253563     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2010.493895     Document Type: Article

References (19)

1. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1-248.
2. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic eval-uation. Health Technol Assess 2007;11:1-158, iii-iv.
3. Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, et al. Etanercept and infliximab for the treatment of pso-riatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006;10:iii-iv, xiii-xvi, 1-239.
4. Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A, et al. Systematic review and economic evaluation of the effective-ness of infliximab for the treatment of Crohn's disease. Health Technol Assess 2003;7:1-67.
5. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20: 138-44. (Pubitemid 351339884)
6. Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year fol-low-up of 1839 patients in southern Sweden. Ann Rheum Dis 2008;67:37-42.
7. Neovius M, Simard J, Sundstrom A, Jacobsson L, Geborek P, Saxne T, et al. Generalizability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. Ann Rheum Dis 2010 (in press).
8. Coyte PC, Croxford R, Asche CV, To T, Feldman W, Friedberg J. Physician and population determinants of rates of middle-ear sur-gery in Ontario. J Am Med Assoc 2001;286:2128-35. (Pubitemid 34041598)
9. Roos NP. Hysterectomy: variations in rates across small areas and across physicians' practices. Am J Public Health 1984;74: 327-35. (Pubitemid 14174995)
10. McPherson K, Wennberg JE, Hovind OB, Clifford P. Small-area variations in the use of common surgical procedures: an inter-national comparison of New England, England, and Norway. N Engl J Med 1982;307:1310-14. (Pubitemid 12005666)
11. Bergstrom G, Karlberg I. Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a manage-ment perspective. Health Policy 2007;81:358-67. (Pubitemid 46436193)
12. van Vollenhoven RF, Klareskog L. Infliximab dosage and infu-sion frequency in clinical practice: experiences in the Stock-holm biologics registry STURE. Scand J Rheumatol 2007;36: 418-23. (Pubitemid 350293517)
13. Kristensen LE, Geborek P, Saxne T. Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swed-ish Arthritis Treatment Group register. Rheumatology (Oxford) 2009;48:243-5.
14. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12. (Pubitemid 43799167)
15. Neovius M, Simard J, Askling J, for the ARTIS Study Group. Nation-wide prevalence of rheumatoid arthritis in Sweden. In: Abstracts of the European League against Rheumatism (EULAR) Congress 2010. June 16-19, 2010; Rome, Italy. Abstract [SAT0489].
16. Jonsson B, Kobelt G, Smolen J. The burden of rheumatoid arthri-tis and access to treatment: uptake of new therapies. Eur J Health Econ 2008;8(Suppl 2):S61-86.
17. Paul-Shaheen P, Clark JD, Williams D. Small area analysis: a review and analysis of the North American literature. J Health Polit Policy Law 1987;12:741-809. (Pubitemid 18019094)
18. Chassin MR. Explaining geographic variations. The enthusiasm hypothesis. Med Care 1993;31(Suppl):YS37-44.
19. Blumenthal D. The variation phenomenon in 1994. N Engl J Med 1994;331:1017-18. (Pubitemid 24304591)